Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 168

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 168
---
100,000 in consideration for Melior’s
waiver of Bukwang’s obligation to pay patent costs pursuant to the Bukwang License, and Melior will take back responsibility for
all tolimidone patent prosecution and maintenance costs.

CMS License Agreement.On January 29, 2019, we entered into the CMS License Agreement with CMS, as guarantor, and the Licensees. The CMS License Agreement
was effective as of February 26, 2019. Pursuant to the terms of the CMS License Agreement, we agreed to license to the Licensees the exclusive
right to use our technology and our intellectual property rights and information and data related to certain of our clinical and pre-clinical
products, including MTX110, together with any other pipeline products or line extensions which are in or which enter pre-clinical or clinical
development in the first three years following the effective time of the CMS License Agreement, together the Products, to develop and
commercialize the Products in China, including Macau, Hong Kong and Taiwan, with the same rights in certain countries in south east Asia
in respect of which the Licensees notifies us that such licensee wants a license after the grant of a regulatory approval of any of the
Products by the FDA, EMA or by the regulatory authorities in the United Kingdom, France, Germany or Switzerland, collectively the Territory,
such activities to be conducted by the Licensee(s) and affiliates of CMS and local partners as permitted sub-licensees. The Licensees
have the exclusive right to import, obtain market approvals and register, market, distribute, promote and sell the Products in the Territory
at the Licensees’ sole discretion, and in the event we choose not to or fail to meet the Licensees’ binding orders for the
Products under certain circumstances, will be granted the right to manufacture the Products itself. The Licensees will be restricted from
supplying the Products to any customers outside of the Territory, while we will be restricted from supplying the Products into the Territory,
except through the Licensees.

We will manufacture the Products
for the Licensees and their sub-licensees, which Products will be subject to exclusive purchase and supply arrangements with the Licensees
for the Territory.

Further, we agreed to permit
the Licensees to identify their own product and line extension targets in respect of which, if we agree, we will carry out initial development
and then will, for a technology transfer fee, the amount of which will be dependent on the circumstances, transfer the specific